P. Rutgeerts

15.0k total citations · 4 hit papers
189 papers, 11.0k citations indexed

About

P. Rutgeerts is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, P. Rutgeerts has authored 189 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Genetics, 88 papers in Epidemiology and 78 papers in Surgery. Recurrent topics in P. Rutgeerts's work include Inflammatory Bowel Disease (118 papers), Microscopic Colitis (78 papers) and Eosinophilic Esophagitis (32 papers). P. Rutgeerts is often cited by papers focused on Inflammatory Bowel Disease (118 papers), Microscopic Colitis (78 papers) and Eosinophilic Esophagitis (32 papers). P. Rutgeerts collaborates with scholars based in Belgium, United States and Canada. P. Rutgeerts's co-authors include Séverine Vermeire, Martin Hiele, Karel Geboes, Gert Van Assche, Raymond Kerremans, Marc Peeters, G. Vantrappen, Geert D’Haens, Jan Beyls and Maja Noman and has published in prestigious journals such as The Lancet, Gastroenterology and Gut.

In The Last Decade

P. Rutgeerts

183 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predictability of the postoperative course of Crohn's disease

1990 1.3k citations P. Rutgeerts, Karel Geboes et al. Gastroenterology profile →
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

2007 798 citations William J. Sandborn, S. B. Hanauer et al. Gut profile →
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

1998 668 citations Geert D’Haens, Karel Geboes et al. Gastroenterology profile →
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

1991 582 citations P. Rutgeerts, Marc Peeters et al. profile →

Peers

Countries citing papers authored by P. Rutgeerts

Since Specialization

Citations

This map shows the geographic impact of P. Rutgeerts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Rutgeerts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Rutgeerts more than expected).

Fields of papers citing papers by P. Rutgeerts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Rutgeerts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Rutgeerts. The network helps show where P. Rutgeerts may publish in the future.

Co-authorship network of co-authors of P. Rutgeerts

This figure shows the co-authorship network connecting the top 25 collaborators of P. Rutgeerts. A scholar is included among the top collaborators of P. Rutgeerts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Rutgeerts. P. Rutgeerts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy 2018 ·Alimentary Pharmacology & Therapeutics ·William J. Sandborn, P. Rutgeerts, C Gasink, Jürgen M. Stein, Bin Zou, Jewel Johanns, Bruce E. Sands, Stephen B. Hanauer, Stephan R. Targan, Subrata Ghosh, Willem J.S. de Villiers, Jean‐Frédéric Colombel, Brian G. Feagan	115
2	Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis 2017 ·Alimentary Pharmacology & Therapeutics ·Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch, Laurent Peyrin‐Biroulet, Remo Panaccione, P. Rutgeerts, Stephen B. Hanauer, Subrata Ghosh, Gert Van Assche, Anne Robinson, Winnie Lau, (unknown), B Huang, Brandee Pappalardo, Holly A. Read	32
3	Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel disease 2015 ·Alimentary Pharmacology & Therapeutics ·Triana Lobatón, Marc Ferrante, P. Rutgeerts, Vera Ballet, Gert Van Assche, Séverine Vermeire	129
4	P386 Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease 2014 ·Journal of Crohn s and Colitis ·G D’Haens, William J. Sandborn, P. Rutgeerts, J.F. Colombel, (unknown), Ofer Spiegelstein, (unknown), (unknown)	3
5	P338 Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence 2014 ·Journal of Crohn s and Colitis ·Marc Ferrante, (unknown), Dana Ďuricová, Geert D’Haens, Séverine Vermeire, Eleftherios Archavlis, P. Rutgeerts, Martin Bortlík, G. Mantzaris, Gert Van Assche	2
6	Anti-TNF induced skin manifestations in IBD patients: characterization and search for predisposing factors 2011 ·Open Repository and Bibliography (University of Liège) ·Isabelle Cleynen, Wouter Van Moerkercke, Niels Vande Casteele, (unknown), Christine Breynaert, Damjana Drobne, (unknown), (unknown), Kristel Van Steen, Maja Noman, Gert Van Assche, P. Rutgeerts, Siegfried Segaert, Séverine Vermeire	5
7	Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease 2011 ·Open Repository and Bibliography (University of Liège) ·David Drobne, Peter Bossuyt, Christine Breynaert, Niels Vande Casteele, Griet Compernolle, (unknown), Isabelle Cleynen, (unknown), Kristel Van Steen, Ann Gils, P. Rutgeerts, Séverine Vermeire, Gert Van Assche	2
8	Effect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease 2008 ·Open Repository and Bibliography (University of Liège) ·Ingrid Arijs, Roel Quintens, Leentje Van Lommel, Kristel Van Steen, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, K. Geboes, Frans Schuit, P. Rutgeerts	1
9	Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort 2008 ·Gut ·Fabian Schnitzler, Herma H. Fidder, Marc Ferrante, Maja Noman, Ingrid Arijs, Gert Van Assche, Ilse Hoffman, Kristel Van Steen, Séverine Vermeire, P. Rutgeerts	413
10	Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2 2007 ·The American Journal of Gastroenterology ·William J. Sandborn, P. Rutgeerts, Brian G. Feagan, Walter Reinisch, A. Olson, Jewel Johanns, Jing Lü, Daniel Rachmilewitz, S. B. Hanauer, Gary Lichtenstein, (unknown), Daniel H. Present, Bruce E. Sands, J F Colombel	2
11	Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease 2006 ·The American Journal of Gastroenterology ·William J. Sandborn, J F Colombel, P. Rutgeerts, Robert Enns, S. B. Hanauer, Remo Panaccione, Stefan Schreiber, Kathleen G. Lomax, P Pollack	1
12	Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy 2006 ·The American Journal of Gastroenterology ·William J. Sandborn, P. Rutgeerts, Robert Enns, S. B. Hanauer, J F Colombel, Remo Panaccione, Jeffrey D. Kent, P Pollack	19
13	Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients 2005 ·The American Journal of Gastroenterology ·William J. Sandborn, Jean‐Frédéric Colombel, Walter Reinisch, Brian G. Feagan, Daniel Rachmilewitz, A. Olson, Jewel Johanns, Suzanne Travers, (unknown), Bruce E. Sands, Stephen B. Hanauer, (unknown), Willem J.S. de Villiers, P. Rutgeerts	5
14	Remission and Clinical Response Induced and Maintained in Patients with Active Crohnʼs Disease Treated for 1-Year Open-Label with Adalimumab 2005 ·The American Journal of Gastroenterology ·William J. Sandborn, Stephen B. Hanauer, (unknown), Douglas C. Wolf, Kim L. Isaacs, Donald MacIntosh, Remo Panaccione, P. Rutgeerts, P Pollack	4
15	Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients 2005 ·The American Journal of Gastroenterology ·Brian G. Feagan, P. Rutgeerts, S. B. Hanauer, S. Yan, D. Eisenberg, Jewel Johanns, (unknown), William J. Sandborn	2
16	Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study 2005 ·The American Journal of Gastroenterology ·S. B. Hanauer, William J. Sandborn, P. Rutgeerts, Richard N. Fedorak, Remo Panaccione, (unknown), P Pollack	0
17	Lactulose administration in healthy volunteers is associated with a reduced b-glucuronidase activity and an increase in fecal bifidobacteria 2005 ·Gut ·(unknown), (unknown), Tom Vanhoutte, Geert Huys, Jean Swings, P. Rutgeerts, Kristin Verbeke	1
18	Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum breakdown → 1998 ·Gastroenterology ·Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts	668
19	Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: need for standardisation. 1994 ·Gut ·Marc Peeters, Martin Hiele, Yvo Ghoos, (unknown), Karel Geboes, G. Vantrappen, P. Rutgeerts	34
20	Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. 1985 ·Gut ·P. Rutgeerts, F. Van Gompel, Karel Geboes, G. Vantrappen, L Broeckaert, Georges Coremans	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact